Amplium

Quick links to important sections

Amplium

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amplium

What is Amplium? A Factual Overview

The drug Amplium is a Fixed-Dose Combination (FDC) product, categorized as a synthetic broad-spectrum antimicrobial agent intended for localized application.

Property Description
Active ingredient Miconazole Nitrate and Tinidazole (FDC)
Form Vaginal Ovules (Suppositories) or Topical Cream
Pharmacological class Broad-spectrum antimicrobial (Antifungal / Antiprotozoal)
Common use Addressing mixed microbial vaginal infections
Origin Synthetic compound

What Type of Drug is Amplium and What is its Composition?

Amplium is defined as a prescription-only medicine that leverages the combined efficacy of two distinct active ingredients: Miconazole Nitrate and Tinidazole. This combination places it within the high-level pharmacological class of antimicrobial agents used for gynecological antiinfectives. The Miconazole component, an imidazole derivative, is a recognized antifungal agent, while the Tinidazole component, a nitroimidazole derivative, provides necessary antiprotozoal and specific antibacterial activity. This dual-agent approach secures broader microbial coverage in a single product.

Understanding Amplium's Form and General Purpose

The preparation is specifically intended for topical administration via the intravaginal route, typically provided in the dosage form of vaginal ovules (suppositories) or a topical cream. The general purpose of Amplium is to capitalize on the synergistic actions of its two components against the spectrum of common causes of mixed vaginal infections. The combination's dual capacity, utilizing Miconazole's action against fungi and Tinidazole's action against protozoa and certain bacteria, makes the medicine generally useful for conditions such as certain forms of vaginosis or vulvovaginitis, ensuring comprehensive attack from a singular unit.

What side effects are possible with Amplium?

Possible Side Effects and Safety Information

The safety profile of Amplium (Miconazole Nitrate and Tinidazole FDC) describes officially documented adverse reactions based on their classification in governmental regulatory documents. The side effects are categorized by frequency and the body system affected, ensuring a neutral, descriptive account of the medicine's safety characteristics.

Frequency-Classified Adverse Reactions

Adverse reactions are broadly divided into those localized to the application site and systemic effects. Common localized effects include a burning sensation, irritation, and pruritus (itching) at the application site. Systemic effects, mainly attributed to the Tinidazole component's absorption, are also frequently documented and include metallic taste, nausea, vomiting, abdominal cramps, and headache.

Less frequently, rare adverse reactions may involve serious outcomes, such as severe neurological events or hypersensitivity.

Serious Safety Constraints and Warnings

Official regulatory labels explicitly document serious safety considerations. These include warnings regarding the potential for peripheral neuropathy and seizures, which may necessitate discontinuation of the medicine if neurological symptoms arise. Rare but severe hypersensitivity reactions, such as Stevens-Johnson syndrome, have been reported with the drug's components.

Specific safety restrictions apply to vulnerable populations. The medicine is contraindicated during the first trimester of pregnancy. Furthermore, nursing is generally discouraged during treatment and for 72 hours following the last dose, due to the drug’s components passing into breast milk.

Time-Related Patterns and Safety Limitations

Local adverse reactions may be more pronounced at the beginning of treatment. Conversely, the risk of serious side effects, such as peripheral neuropathy, is often associated with prolonged exposure or repeated courses. A critical safety constraint requires the avoidance of alcohol during treatment and for 72 hours afterward due to the risk of a severe disulfiram-like reaction.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose concerns for the Amplium fixed-dose combination primarily relate to potential high systemic exposure following accidental oral ingestion of the topical formulation. Regulatory documentation outlines specific manifestations and emergency procedures for such events, focusing on the systemic toxicity profile of its components.

Documented Overdose Manifestations

Officially documented presentations of overdose include severe gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea. Systemic effects, including dizziness, persistent metallic taste, and headache, are also listed in regulatory profiles.

Severe Outcomes and Required Action

A critical concern documented by regulatory authorities is the risk of severe neurotoxicity. This can manifest as peripheral neuropathy (numbness, tingling), ataxia (lack of coordination), and the potential for convulsions (seizures).

Regulatory agencies mandate that individuals must seek immediate medical attention or contact emergency services upon suspected overdose or the manifestation of these severe neurological signs. Treatment must be discontinued immediately if abnormal neurological signs are observed.

Supportive Management

Management of the overdose is officially defined as symptomatic and supportive treatment. Regulatory information confirms that no specific antidote is known. In cases of recent, acute oral ingestion, procedures such as gastric lavage may be considered, and the active component Tinidazole is known to be easily dialyzable.

Therapeutic Uses of Amplium

What Amplium Treats: Main Uses and Benefits

Amplium is used across domains where additional symptomatic support is needed in the context of infectious vaginitis, relevant in clinical settings that involve acute or unstable symptom patterns. The components of this medication are commonly used to help with conditions presenting with localized discomfort, relevant to vaginitis.

It is primarily applied in addressing mixed microbial infections (vulvovaginitis), which are conditions characterized by the presence of multiple pathogens. The medication is commonly used across conditions presenting with acute episodes for indications such as vaginal candidiasis (fungal), trichomoniasis (protozoal), and certain types of bacterial vaginosis. This is relevant across acute therapeutic contexts and helps provide short-term symptomatic assistance for conditions involving episodic or fluctuating manifestations.

The medication is relevant in contexts marked by increased discomfort, as it helps address symptom clusters that may become intense or disruptive, such as intense vaginal itching (pruritus), localized burning, and irritation. The treatment provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Symptom Management

Amplium is relevant for easing symptoms related to inflammatory or irritative states, supporting general well-being during symptomatic phases when discomfort is heightened.

Regulatory References

  1. World Health Organization Guidelines on Symptomatic STI Management

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed: Adults and adolescents 12 years of age and over, with standard adult use generally applied for older adults (65 years and older).

Populations for whom use is contraindicated: Use is strictly prohibited for patients with known hypersensitivity to Miconazole, Tinidazole, or other similar imidazole derivatives. The medicine is also contraindicated in women during the first trimester of pregnancy and in nursing mothers unless breastfeeding is suspended for 72 hours following the final dose. Absolute prohibitions apply to patients with recent Disulfiram use or current consumption of alcohol for at least three days post-treatment. Use is also prohibited in patients with Cockayne syndrome.

Age and Condition-Specific Rules

Age-related eligibility rules: The product is not to be used in children under 12 years of age, nor is it recommended for virgins or young women who are not sexually mature.

Condition-specific eligibility rules: Use is classified as conditional or requires caution for patients with a history of blood disorders, certain neurological conditions, or severe hepatic (liver) impairment. Conditional use also applies to patients taking oral anticoagulants like Warfarin.

Reproductive Status and Restrictions

Pregnancy and lactation eligibility status: In the second and third trimesters, use is restricted to cases where it is clearly needed.

Eligibility-related restrictions: The suppository formulation is not recommended for concurrent use with latex contraceptive devices (condoms or diaphragms) due to the risk of damage.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for the active components of Amplium (Miconazole Nitrate and Tinidazole) dictates specific constraints and required monitoring, as documented in government regulatory labels.

Formal Interaction Restrictions

Classification Restriction and Interacting Substance
Contraindicated Co-administration with Disulfiram is prohibited if it has been taken within the 14 days prior to starting treatment.
Mandatory Avoidance Consumption of alcohol-containing preparations is prohibited during therapy and for at least three days after the final dose. This includes products containing Propylene Glycol.

Pharmacokinetic and Pharmacodynamic Interactions

Oral Anticoagulants: Both the Miconazole and Tinidazole components are documented to potentiate the effects of oral coumarin anticoagulants, such as Warfarin. This pharmacodynamic enhancement can lead to an increase in prothrombin time (INR) and requires close regulatory monitoring.

Metabolic Modifiers: The Miconazole component is officially documented as an inhibitor of CYP2C9 and CYP3A4, which can reduce the clearance and increase the exposure of co-administered drugs that are substrates for these enzymes. The Tinidazole component may also increase the serum concentrations of substances like Lithium, Cyclosporine, Tacrolimus, and Fluorouracil due to reduced clearance.

Mechanism of Action

Inhibition of Bacterial Cell Wall Synthesis

This core mechanism involves Amplium, a beta-lactam antibiotic, acting as an irreversible inhibitor by binding covalently to and inactivating Penicillin-Binding Proteins (PBPs). These transpeptidase enzymes are essential catalysts for the final cross-linking step in peptidoglycan synthesis, which provides structural integrity to the bacterial cell wall. The resulting cessation of cross-linking disrupts the formation of the rigid cell wall structure, creating a fatal vulnerability. This loss of structural integrity causes a severe osmotic imbalance, ultimately leading to cell lysis of the susceptible bacteria.


Targeting Broad-Spectrum Bacterial PBPs

The chemical structure of Amplium facilitates its penetration through the outer membrane of certain Gram-negative bacteria, enabling access to a wider spectrum of PBPs across diverse pathogens. This expanded binding results in the simultaneous inhibition of multiple bacterial cell replication pathways and survival mechanisms, contributing to a substantial reduction in the viable bacterial load within the affected biological system.

Dosage and Administration Information

How to Use Amplium: Official Administration Guidelines

Amplium, a Fixed-Dose Combination (FDC) product containing Miconazole Nitrate and Tinidazole, is designed for localized anti-infective treatment. Its official administration is strictly topical, using a vaginal ovule (suppository) for the intravaginal route and an accompanying topical cream for external application. The use pattern is based on a fixed, short course, generally administered for 3 days or 7 consecutive days.

The dosing regimen requires the insertion of one ovule per administration, which is typically scheduled to be used once daily at bedtime (qHS). This timing is specified in official instructions to maximize the drug's contact time by aiding retention. If the regimen includes a topical cream, it is applied externally to the vulvar area, usually twice daily, concurrently with the ovule course.

Completing the entire course is a fundamental principle of use. If a dose is missed, the standard approach is to use it as soon as remembered; however, double dosing is strictly prohibited. The product's usage applies to adults and adolescents aged 12 years and older, with no specific high-level dose adjustments documented for older adults or those with renal or hepatic impairment, consistent with its highly localized delivery.

Recent Clinical Evidence

Research evidence / Overview of Studies for Amplium

The clinical evidence for Amplium, a fixed-dose combination product containing Miconazole Nitrate and Tinidazole, is derived from clinical trials and published scientific literature used for regulatory evaluation that primarily focus on addressing infections caused by multiple pathogens. The research examined how the combination of the two active components was evaluated across different study scenarios.


Evidence for Use in Mixed Vaginal Infections (MVIs)

The clinical evaluation of Amplium focuses on addressing mixed vaginal infections, which are conditions characterized by the presence of both fungal and bacterial or protozoal pathogens.

Researchers employed short-term Randomized Controlled Trials (RCTs) and comparative open-label studies to explore this combined approach. These studies included adult women diagnosed with mixed infections. The primary focus of the research was to monitor and measure two key outcomes: clinical cure (defined as the primary outcome of symptom and sign assessment) and microbiological cure (defined as the primary outcome of pathogen clearance).

Findings describe patterns observed in studies and indicate that the combination approach was studied for relevance in trials assessing short-term or episodic symptom patterns linked to mixed pathogens. Research highlights changes measured during the study period concerning both the patient-reported outcomes describing perceived discomfort and the evolution of laboratory markers. These trials reported measurements of short-term cure rates over observation periods, often extending to 30 days.


Scientific Gaps and Unanswered Research Questions

The research contributes to the broader evidence landscape but highlights several areas where the findings are not yet conclusive or where the data are still emerging.

A key limitation is that follow-up durations were limited in many studies, meaning that the full picture of long-term infection patterns is not fully established. Additionally, evidence quality varies across studies, particularly when comparing the specific Miconazole/Tinidazole FDC to other, chemically similar combinations for which more research may exist.

Comparative evidence is lacking when assessing this topical FDC directly against modern oral systemic treatments for some component pathogens. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References WHO Guidelines on Symptomatic STI Management (Table excerpt on Vaginitis Agents)

Frequently Asked Questions (FAQ)

Common questions about Amplium (FAQ)

Q: How is Amplium different from other medicines that treat the same condition?

Amplium is defined in official product information as a Fixed-Dose Combination (FDC) product that contains two distinct active ingredients, Miconazole Nitrate and Tinidazole. According to its pharmacological classification, this combination approach is intended to provide broad coverage against both fungal and bacterial or protozoal pathogens in a single product.

Q: Does Amplium require special monitoring after starting treatment?

Regulatory documents specify that close monitoring may be needed when the product is co-administered with oral anticoagulants such as Warfarin. Monitoring is also required for the appearance of abnormal neurological signs, as this may necessitate discontinuation of the medicine.

Q: What foods or beverages might interfere with Amplium?

Official drug information indicates that the consumption of alcohol or any alcohol-containing preparations is strictly prohibited during therapy and for a period of at least three days after the final dose. This mandatory avoidance rule also includes products that contain Propylene Glycol.

Q: Is Amplium generally considered appropriate for people with kidney problems?

Pharmacokinetic studies of the active components indicate that there are no significant differences in the drug's systemic action in people with severe kidney impairment compared to healthy subjects. As a result, no specific dose adjustments are typically documented for this localized route of administration.

Q: What does the latest research say about the long-term use of Amplium?

Official safety constraints caution that the risk of certain serious side effects, such as peripheral neuropathy (nerve damage), is often associated with prolonged exposure or repeated courses. Regulatory research summaries also note that the follow-up durations were limited in many studies, meaning that the long-term effects on infection patterns are not fully established.

Q: Do I need to change my diet while I'm on Amplium?

Official documents indicate that the consumption of any alcohol or alcohol-containing preparations is prohibited during therapy and for at least three days following the final dose.

Q: What are the signs of a non-severe allergic reaction to Amplium?

Regulatory documents confirm signs of hypersensitivity reactions, which can include symptoms such as hives, itching, or rash. Official safety information advises that the product should be discontinued immediately at the first signs of a reaction.

Q: What makes Amplium work differently from other medicines in the same class?

Amplium utilizes a dual mechanism of action through its two components. The Miconazole component works as an antifungal, while the Tinidazole component provides specific antiprotozoal and antibacterial effects, resulting in a combination treatment for mixed infections.

Q: Are there any documented drug-drug interactions that are considered minor?

Official interaction profiles classify certain documented interactions as “minor.” This classification indicates a minimally clinically significant risk where minimizing the risk or instituting a monitoring plan is typically deemed appropriate.

Q: Is Amplium considered a high-risk medication by regulators?

Regulatory documents provide a neutral, descriptive account of the medicine’s safety characteristics. This includes listing potential adverse reactions, such as serious safety constraints like seizures and peripheral neuropathy, and providing specific contraindications and warnings required for the product.

Q: Have there been many large, well-controlled clinical trials conducted on Amplium?

The clinical evidence supporting the regulatory evaluation of Amplium is derived from clinical trials, including short-term Randomized Controlled Trials (RCTs) and comparative open-label studies. These studies specifically focused on assessing the combination's use in mixed vaginal infections.

Q: Do I need to take Amplium at the exact same time every day for it to work correctly?

Official instructions state that the ovule is typically scheduled for use once daily at bedtime. Regulatory guidance notes that a missed dose may be used as soon as it is remembered, but strictly prohibits the taking of a double dose.

Q: How long does it take for Amplium to fully leave the body?

The elimination half-life of the Tinidazole component is approximately 12 to 14 hours. Following topical application, the Miconazole component is only minimally absorbed into the systemic circulation.

Q: Is it normal to feel a bit dizzy when you first start taking Amplium?

Dizziness is documented as an adverse reaction that may occur. This effect is typically attributed to the minimal systemic absorption of the Tinidazole component.

Q: Can Amplium cause weight changes?

Weight loss is listed as an infrequently reported adverse reaction associated with one of the active components, Tinidazole.

Q: Can Amplium be taken with over-the-counter pain relievers?

Official interaction profiles list certain common over-the-counter pain relievers, such as acetaminophen and ibuprofen. Their interaction classifications range from minor to moderate.

Q: Does Amplium interact with common supplements like vitamins or minerals?

Official interaction profiles list certain common supplements, such as various vitamins and fish oil, as having documented interactions with the active components of the medicine.

Q: Why are there different versions or strengths of Amplium?

The active components are available in different strengths and formulations, such as the intravaginal ovule and the topical cream. These are intended to provide flexibility for the specified treatment regimens.

Q: Does Amplium contain any common allergens like lactose or gluten?

The excipients (inactive ingredients) for the specific product formulation are listed in the official documents. Hypersensitivity to certain components, such as milk protein concentrate, has been documented with some miconazole products.

Q: If I accidentally take an extra dose of Amplium, what should I look for?

Overdosage of the Miconazole component in humans has not been officially reported to date. Regarding the Tinidazole component, the regulatory safety profile indicates that severe neurological events are known adverse reactions that require monitoring.

Q: Is Amplium a controlled substance?

Official classifications define Amplium as a prescription-only medicine. It is not classified as a controlled substance under government regulatory schedules.

Q: Can taking Amplium affect my sleep schedule?

Trouble sleeping or feeling drowsy are documented as less common adverse reactions associated with the Tinidazole component of the medicine.

Q: Does Amplium have a warning label about operating heavy machinery or driving?

Warnings advise that the medicine may cause dizziness or drowsiness. The official product label instructs that patients should avoid operating heavy machinery or driving until the effects on alertness are known.

How should Amplium be stored and disposed of?

Official Storage and Disposal Instructions for Amplium

Regulatory labeling for Amplium (Miconazole Nitrate and Tinidazole ovules/cream) dictates precise conditions for storage and disposal to maintain product integrity and safety.

Storage Requirements

The medicine must be stored at controlled room temperature, typically below 25 C or 30 C. It is mandatory to keep the product in its original packaging and protect it from heat, light, and moisture. Storage in environments such as a refrigerator or freezer is prohibited as it may compromise the physical integrity of the formulation.

Safety and Disposal

All medicines, including Amplium, must be kept out of the sight and reach of children. The product must not be used after the printed expiry date. For disposal, unused or expired Amplium should not be discarded via wastewater or household waste. Disposal must be performed according to local regulations, often involving community medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amplium found in:

A-Z Index: